DexCom (DXCM) Appoints Renée Galá to its Board

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025.

Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals Public Limited Company, a global biopharmaceutical company with greater than $4 billion in total revenues in 2024 whose purpose is to innovate to transform the lives of patients and their families. In this role for Jazz Pharmaceuticals, Ms. Galá oversees global business operations including commercial operations, research and development, manufacturing, corporate strategy and quality. She brings to the Dexcom Board a strong track record of strategic and financial leadership at high-growth companies, including oversight of key international expansion initiatives and business development collaborations.

“We are excited to announce Renée’s appointment to the Dexcom Board today and benefit from her insights,” said Kevin Sayer, chairman, president and CEO at Dexcom. “Dexcom has a unique opportunity ahead of us to empower greater metabolic health for millions of people around the world. Renée’s extensive experience guiding global finance and global operations including commercial and R&D to drive growth and create shareholder value provides an excellent fit at this key point in Dexcom’s journey.”

You May Also Be Interested In

• Jennifer Hyman to retire from Estee Lauder board in November
• CalciMedica (CALC) files for 56.02M share offering by selling stockholders
• Elme Communities cuts liquidating distribution estimate after Riverside deal